Voyager Therapeutics (VYGR) Non-Current Deffered Revenue (2014 - 2025)

Voyager Therapeutics has reported Non-Current Deffered Revenue for 12 years, with the latest figure at $1.5 million in Q3 2025.

• Quarterly Non-Current Deffered Revenue fell 87.9% year-over-year to $1.5 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $1.5 million (down 87.9% YoY) and the FY2024 annual result came in at $6.0 million, down 81.45% from the prior year.
• Non-Current Deffered Revenue slipped to $1.5 million in Q3 2025 per VYGR's latest filing, from $2.6 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $78.9 million in Q1 2023 and troughed at $1.5 million in Q3 2025.
• A 5-year average of $20.7 million and a median of $12.2 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2023 and 2025: Non-Current Deffered Revenue surged 833.51% in 2023, then slumped 87.9% in 2025.
• Over 5 years, Non-Current Deffered Revenue stood at $8.2 million in 2021, then dropped by 21.44% to $6.4 million in 2022, then soared by 401.69% to $32.4 million in 2023, then tumbled by 81.45% to $6.0 million in 2024, then plunged by 75.5% to $1.5 million in 2025.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $1.5 million, $2.6 million, and $4.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.